LivaNova (NASDAQ:LIVN) Price Target Raised to $61.00

LivaNova (NASDAQ:LIVN) had its price target boosted by stock analysts at Robert W. Baird from $55.00 to $61.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 38.45% from the stock’s previous close.

Several other analysts also recently issued reports on the stock. Stifel Nicolaus lowered their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of LivaNova in a research note on Monday, March 17th. The Goldman Sachs Group decreased their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Finally, Mizuho reduced their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.17.

LivaNova Price Performance

LIVN stock opened at $44.06 on Thursday. The firm has a market cap of $2.40 billion, a P/E ratio of 104.90 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 1 year low of $32.48 and a 1 year high of $63.57. The stock has a 50-day simple moving average of $37.89 and a 200-day simple moving average of $45.20.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of LivaNova by 13.5% in the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock valued at $104,755,000 after acquiring an additional 316,993 shares during the last quarter. Capital Research Global Investors increased its stake in LivaNova by 19.1% during the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after purchasing an additional 258,730 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of LivaNova by 8.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock worth $60,710,000 after purchasing an additional 107,693 shares during the period. Redmile Group LLC raised its holdings in shares of LivaNova by 19.3% during the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company’s stock worth $48,326,000 after purchasing an additional 168,500 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in shares of LivaNova by 0.6% in the 4th quarter. Nuveen Asset Management LLC now owns 823,412 shares of the company’s stock worth $38,132,000 after buying an additional 5,080 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.